You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Additional costs related to formulation, chronic tox and general development of PTI-125

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. sHLA Protein Chip

    SBC: GENOMICS USA, INC.            Topic: NIAID

    Abstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Airborne Radar Conflict Avoidance for Triton and Fire Scout

    SBC: RDRTEC INCORPORATED            Topic: N13AT003

    RDRTec’s RACAS’s Active Element Scanned Array design approach to meet collision avoidance performance, SWaPC and cost goals utilizes RDRTec’s unique array topology.RDRTec has been developing, enhancing, and extending the Common Radar Airborne Collision Avoidance System (C-RACAS) and associated modeling and simulation tools for non-cooperative conflict avoidance for both Triton and Fire Scout ...

    SBIR Phase II 2018 Department of DefenseNavy
  4. AMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATION

    SBC: NANOSCOPE TECHNOLOGIES LLC            Topic: NEI

    Severe loss of vision occurs due to age-related macular degeneration (AMD) and approximately 15 million people in the US have some form of AMD, which is expected to double by 2050. Most of the current clinical treatments are primarily focused on slowing down the progression of the disease, as there is neither a cure that can stop the degeneration nor a therapy, other than retinal prostheses, that ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs

    SBC: RADIOMEDIX, INC.            Topic: NCI

    A peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resista ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. High Performance Energetic Propellant Ingredient Process Research and Development

    SBC: NALAS ENGINEERING SERVICES INC            Topic: N16AT021

    CL-20 is the most powerful conventional explosive known, but its high cost has limited its adoption in a range of potential applications. Par of the challenge in making these materials is the complexity of the reaction used to prepare the polycyclic cage. The complexity of this reaction makes it difficult to have insight into the reaction and to improve it. Additionally, several of the intermediat ...

    STTR Phase II 2018 Department of DefenseNavy
  9. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Methodologies for Cost-Effective Measurement of Dynamic Material Properties or Characterization of Materials under Dynamic Loads

    SBC: PROTECTION ENGINEERING CONSULTANTS LLC            Topic: MDA16T003

    Explosions and high-velocity impacts can create strain rates on the order of 105 to 107 s-1. To simulate these events, first-principles codes require material models that are valid at these loading rates. Currently, the amount of test data, material models and material constants for this strain rate range is extremely limited, and an innovative and cost-effective laboratory test procedure is neede ...

    STTR Phase II 2018 Department of DefenseMissile Defense Agency
US Flag An Official Website of the United States Government